Laboratory Co. of America (NYSE:LH - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, April 29th. Analysts expect Laboratory Co. of America to post earnings of $3.75 per share and revenue of $3.41 billion for the quarter. Laboratory Co. of America has set its FY 2025 guidance at 15.600-16.400 EPS.
Laboratory Co. of America (NYSE:LH - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, analysts expect Laboratory Co. of America to post $16 EPS for the current fiscal year and $18 EPS for the next fiscal year.
Laboratory Co. of America Stock Performance
LH traded up $0.02 on Friday, reaching $228.60. The stock had a trading volume of 907,300 shares, compared to its average volume of 633,498. The business's 50-day moving average price is $235.30 and its two-hundred day moving average price is $235.01. The company has a market cap of $19.13 billion, a P/E ratio of 25.92, a price-to-earnings-growth ratio of 1.71 and a beta of 0.99. Laboratory Co. of America has a 12-month low of $191.97 and a 12-month high of $258.59. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67.
Laboratory Co. of America Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 11th. Investors of record on Thursday, May 29th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.26%. Laboratory Co. of America's dividend payout ratio is presently 32.65%.
Analyst Upgrades and Downgrades
Several analysts have commented on LH shares. StockNews.com lowered Laboratory Co. of America from a "buy" rating to a "hold" rating in a report on Friday, April 18th. Redburn Atlantic assumed coverage on shares of Laboratory Co. of America in a report on Wednesday, April 2nd. They issued a "buy" rating and a $276.00 price target for the company. Piper Sandler increased their price objective on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Jefferies Financial Group upped their price target on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Finally, Citigroup upgraded Laboratory Co. of America from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $250.00 to $300.00 in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Laboratory Co. of America has a consensus rating of "Moderate Buy" and a consensus target price of $268.77.
Read Our Latest Research Report on LH
Insiders Place Their Bets
In other Laboratory Co. of America news, COO Mark S. Schroeder sold 5,339 shares of Laboratory Co. of America stock in a transaction on Friday, February 28th. The stock was sold at an average price of $249.23, for a total value of $1,330,638.97. Following the sale, the chief operating officer now owns 4,960 shares in the company, valued at $1,236,180.80. The trade was a 51.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Adam H. Schechter sold 6,121 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total value of $1,497,319.02. Following the transaction, the chief executive officer now owns 86,445 shares of the company's stock, valued at approximately $21,146,175.90. This represents a 6.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,258 shares of company stock valued at $3,518,177 in the last three months. 0.84% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Laboratory Co. of America stock. Brighton Jones LLC bought a new stake in Laboratory Co. of America Holdings (NYSE:LH - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 4,321 shares of the medical research company's stock, valued at approximately $991,000. 95.94% of the stock is owned by hedge funds and other institutional investors.
About Laboratory Co. of America
(
Get Free Report)
Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Featured Stories
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
